Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) had its price objective decreased by stock analysts at Piper Sandler to $2.00 in a report released on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler‘s price objective would suggest a potential upside of 321.76% from the company’s current price.
A number of other research analysts have also issued reports on the stock. Weiss Ratings lowered shares of Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. BTIG Research reaffirmed a “buy” rating and set a $4.00 target price on shares of Akebia Therapeutics in a report on Tuesday, September 15th. HC Wainwright reiterated a “buy” rating on shares of Akebia Therapeutics in a research report on Thursday, August 6th. Westpark Capital started coverage on Akebia Therapeutics in a research note on Tuesday, September 8th. They issued a “buy” rating and a $4.50 price target for the company. Finally, Leerink Partners downgraded Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 price target on the stock. in a research report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $3.50.
Read Our Latest Analysis on AKBA
Akebia Therapeutics Stock Performance
AKBA stock opened at $0.47 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.24 and a current ratio of 1.36. The company’s 50-day simple moving average is $0.77 and its 200 day simple moving average is $1.10. Akebia Therapeutics has a 52 week low of $0.36 and a 52 week high of $1.83. The company has a market capitalization of $131.67 million, a PE ratio of -2.96 and a beta of 0.24.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). Akebia Therapeutics had a negative net margin of 22.60% and a negative return on equity of 156.59%. The business had revenue of $36.90 million for the quarter, compared to analyst estimates of $46.94 million. As a group, sell-side analysts anticipate that Akebia Therapeutics will post -0.17 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of AKBA. BlackRock Inc. acquired a new position in Akebia Therapeutics during the second quarter valued at approximately $22,784,000. Nantahala Capital Management LLC acquired a new position in Akebia Therapeutics during the second quarter worth about $2,280,000. Bank of New York Mellon Corp acquired a new position in Akebia Therapeutics during the second quarter worth about $706,000. Bank of America Corp DE lifted its holdings in shares of Akebia Therapeutics by 22.4% in the first quarter. Bank of America Corp DE now owns 2,763,362 shares of the biopharmaceutical company’s stock worth $3,841,000 after acquiring an additional 505,951 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in shares of Akebia Therapeutics in the second quarter worth about $369,000. Institutional investors and hedge funds own 33.92% of the company’s stock.
About Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for people affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, the company’s work has centered on anemia and other complications associated with chronic kidney disease. Its products include Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and Auryxia (ferric citrate).
See Also
- Five stocks we like better than Akebia Therapeutics
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
